Birchview Capital, LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Birchview Capital, LP reported 73 stock positions worth $175.7 million. Its top holding was KLA (KLAC) at 16.7% of the portfolio, followed by Bristol-Myers Squibb (BMY, 10.6%) and Compass Therapeutics (CMPX, 4.4%). Compared with Q4 2025, it opened 17 new positions, sold out of 12, added to 11 and reduced 21. The biggest buy was a new position in Relmada Therapeutics (RLMD) and the biggest sale an exit from Amicus Therapeutics (FOLD).
- Most Recent 13F
- Q2 2026
- Location
- BURLINGTON, VT
- CIK
- 0001618205
- Portfolio Value
- $175.7M (Q1 2026)
- SEC Filing
- 0001618205-26-000002 ↗ filed May 15, 2026
Holdings Value
Holdings 73 stocks · $175.7M
| KLAC KLA Corp. | 16.67% | 19,883 | $29.3M | Reduce -9.1% |
| BMY Bristol-Myers Squibb Co. | 10.57% | 306,268 | $18.6M | Add +1.1% |
| CMPX Compass Therapeutics Inc. | 4.41% | 1,465,867 | $7.8M | Reduce -8.0% |
| LRCX Lam Research Corp. | 4.38% | 36,000 | $7.7M | Reduce -10.7% |
| STOK Stoke Therapeutics Inc. | 3.89% | 210,000 | $6.8M | Reduce -19.2% |
| OVV Ovintiv Inc. | 3.63% | 107,500 | $6.4M | No change |
| NTLA Intellia Therapeutics Inc. | 3.25% | 445,400 | $5.7M | Add +41.2% |
| GPCR Structure Therapeutics Inc. | 2.74% | 100,000 | $4.8M | Add +11.1% |
| SLDB Solid Biosciences Inc. | 2.57% | 625,980 | $4.5M | Reduce -11.3% |
| PRTA Prothena Corp. PLC | 2.48% | 449,019 | $4.4M | Add +1.8% |
| BDSX Biodesix Inc. | 2.37% | 286,804 | $4.2M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 2.17% | 171,000 | $3.8M | No change |
| PTGX Protagonist Therapeutics Inc. | 2.10% | 35,000 | $3.7M | Reduce -36.4% |
| NBIX Neurocrine Biosciences Inc. | 2.04% | 27,190 | $3.6M | No change |
| OLMA Olema Pharmaceuticals Inc. | 1.86% | 219,000 | $3.3M | Reduce -18.6% |
| RLMD Relmada Therapeutics Inc. | 1.62% | 409,387 | $2.8M | New |
| OCUL Ocular Therapeutix Inc. | 1.54% | 320,000 | $2.7M | New |
| UTHR United Therapeutics Corp. | 1.52% | 4,500 | $2.7M | Add +50.0% |
| NKTR Nektar Therapeutics | 1.27% | 31,000 | $2.2M | No change |
| CLDX Celldex Therapeutics Inc. | 1.27% | 70,095 | $2.2M | New |
| NVCR Novocure Ltd. | 1.26% | 202,330 | $2.2M | Add +33.0% |
| EQT Eqt Corp. | 1.25% | 34,619 | $2.2M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 1.23% | 195,000 | $2.2M | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 1.22% | 463,599 | $2.2M | Add +0.2% |
| CMPS Compass Pathways PLC | 1.18% | 375,000 | $2.1M | New |
| PACB Pacific Biosciences of Calif | 1.13% | 1,500,000 | $2.0M | Add +200.0% |
| CYTK Cytokinetics Inc. | 1.13% | 30,000 | $2.0M | No change |
| CORT Corcept Therapeutics Inc. | 1.08% | 47,200 | $1.9M | Reduce -29.8% |
| VERA Vera Therapeutics Inc. | 1.01% | 44,000 | $1.8M | No change |
| ALKS Alkermes PLC | 1.01% | 50,000 | $1.8M | No change |
| ENGN Engene Holdings Inc. | 0.97% | 250,000 | $1.7M | New |
| QURE Uniqure NV | 0.94% | 100,697 | $1.6M | Add +227.1% |
| ZBIO Zenas Biopharma Inc. | 0.78% | 70,000 | $1.4M | New |
| QDEL Quidelortho Corp. | 0.77% | 82,548 | $1.4M | Add +13.8% |
| FHTX Foghorn Therapeutics Inc. | 0.77% | 281,730 | $1.3M | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 0.74% | 62,000 | $1.3M | No change |
| XENE Xenon Pharmaceuticals Inc. | 0.70% | 21,000 | $1.2M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 0.65% | 57,000 | $1.1M | No change |
| IMNM Immunome Inc. | 0.62% | 50,000 | $1.1M | Reduce -61.5% |
| FCX Freeport-McMoran Inc. | 0.60% | 18,040 | $1.1M | Reduce -0.0% |
| AXSM Axsome Therapeutics Inc. | 0.58% | 6,000 | $1.0M | Reduce -1.0% |
| BIIB Biogen Inc. | 0.52% | 5,000 | $917K | New |
| LPCN Lipocine Inc. | 0.51% | 111,786 | $893K | New |
| TVTX Travere Therapeutics Inc. | 0.49% | 29,200 | $868K | Reduce -32.1% |
| HROW Harrow Inc. | 0.48% | 24,000 | $846K | Reduce -29.4% |
| PHVS Pharvaris NV | 0.48% | 29,847 | $843K | No change |
| VSTM Verastem Inc. | 0.45% | 150,000 | $795K | No change |
| APGE Apogee Therapeutics Inc. | 0.43% | 9,000 | $758K | Reduce -43.8% |
| HALO Halozyme Therapeutics Inc. | 0.37% | 10,100 | $653K | No change |
| BBIO Bridgebio Pharma Inc. | 0.37% | 8,688 | $645K | No change |
| APLS Apellis Pharmaceuticals Inc. | 0.32% | 14,000 | $563K | No change |
| IDYA Ideaya Biosciences Inc. | 0.32% | 16,860 | $562K | New |
| RCUS Arcus Biosciences Inc. | 0.32% | 25,889 | $559K | New |
| RGNX Regenxbio Inc. | 0.32% | 66,270 | $555K | New |
| KPTI Karyopharm Therapeutics Inc. | 0.27% | 83,952 | $468K | New |
| RCKT Rocket Pharmaceuticals Inc. | 0.26% | 127,025 | $455K | New |
| VRDN Viridian Therapeutics Inc. | 0.22% | 20,100 | $393K | New |
| OM Outset Medical Inc. filed as OUSTER INC A | 0.22% | 98,882 | $380K | Reduce -0.0% |
| LUNG Pulmonx Corp. | 0.18% | 250,221 | $323K | Reduce -0.1% |
| CSTL Castle Biosciences Inc. | 0.18% | 12,900 | $317K | Reduce -84.0% |
| TRIN Trinity Capital Inc. | 0.17% | 20,000 | $294K | No change |
| CADL Candel Therapeutics Inc. | 0.17% | 60,000 | $294K | No change |
| VYGR Voyager Therapeutics Inc. | 0.16% | 74,918 | $289K | No change |
| CGEM Cullinan Therapeutics Inc. | 0.16% | 20,000 | $284K | No change |
| KBDC Kayne Anderson BDC Inc. | 0.16% | 20,000 | $274K | No change |
| GRCE Grace Therapeutics Inc. | 0.13% | 50,000 | $232K | New |
| ELUT Elutia Inc. | 0.10% | 165,094 | $173K | Reduce -37.2% |
| KYNB Kyntra Bio Inc. | 0.09% | 22,566 | $153K | New |
| QNRX Quoin Pharmaceuticals LT-ADR | 0.08% | 20,000 | $132K | New |
| PHR Phreesia Inc. | 0.07% | 14,300 | $120K | Reduce -87.1% |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.02% | 17,503 | $41K | Add +3.0% |
| DCGO Docgo Inc. | 0.01% | 39,573 | $25K | Reduce -20.7% |
| GOSS Gossamer Bio Inc. | 0.00% | 18,176 | $6K | Reduce -86.8% |
Portfolio Sells Q4 2025 → Q1 2026
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −2.11 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -18.6% | 1.86% | −2.08 |
| CSTL Castle Biosciences Inc. | Reduce -84.0% | 0.18% | −1.66 |
| PHR Phreesia Inc. | Reduce -87.1% | 0.07% | −1.03 |
| IMNM Immunome Inc. | Reduce -61.5% | 0.62% | −1.01 |
| STOK Stoke Therapeutics Inc. | Reduce -19.2% | 3.89% | −0.94 |
| PTGX Protagonist Therapeutics Inc. | Reduce -36.4% | 2.10% | −0.71 |
| MASI Masimo Corp. | Sold out | 0.00% | −0.63 |
| CMPX Compass Therapeutics Inc. | Reduce -8.0% | 4.41% | −0.59 |
| TXG 10X Genomics Inc. Class A | Sold out | 0.00% | −0.56 |
| VTYX Ventyx Biosciences Inc. | Sold out | 0.00% | −0.53 |
| HROW Harrow Inc. | Reduce -29.4% | 0.48% | −0.49 |
| TVTX Travere Therapeutics Inc. | Reduce -32.1% | 0.49% | −0.47 |
| ILMN Illumina Inc. | Sold out | 0.00% | −0.46 |
| BIOHAVEN PHARMACEUTICAL HOLD | Sold out | 0.00% | −0.39 |
| TMCI Treace Medical Concepts Inc. | Sold out | 0.00% | −0.33 |
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −0.30 |
| CORT Corcept Therapeutics Inc. | Reduce -29.8% | 1.08% | −0.29 |
| APGE Apogee Therapeutics Inc. | Reduce -43.8% | 0.43% | −0.28 |
| GOSS Gossamer Bio Inc. | Reduce -86.8% | 0.00% | −0.25 |
| ATEC Alphatec Holdings Inc. | Sold out | 0.00% | −0.22 |
| LQDA Liquidia Corp. | Sold out | 0.00% | −0.20 |
| INBX Inhibrx Biosciences Inc. | Sold out | 0.00% | −0.17 |
| LUNG Pulmonx Corp. | Reduce -0.1% | 0.18% | −0.14 |
| AXSM Axsome Therapeutics Inc. | Reduce -1.0% | 0.58% | −0.07 |
| ALMS Alumis Inc. | Sold out | 0.00% | −0.06 |
| DCGO Docgo Inc. | Reduce -20.7% | 0.01% | −0.01 |
| ELUT Elutia Inc. | Reduce -37.2% | 0.10% | −0.01 |
| OM Outset Medical Inc. | Reduce -0.0% | 0.22% | +0.00 |
| FCX Freeport-McMoran Inc. | Reduce -0.0% | 0.60% | +0.07 |
| SLDB Solid Biosciences Inc. | Reduce -11.3% | 2.57% | +0.23 |
| LRCX Lam Research Corp. | Reduce -10.7% | 4.38% | +0.34 |
| KLAC KLA Corp. | Reduce -9.1% | 16.67% | +1.10 |
Portfolio Buys Q4 2025 → Q1 2026
| RLMD Relmada Therapeutics Inc. | New | 1.62% | +1.62 |
| NTLA Intellia Therapeutics Inc. | Add +41.2% | 3.25% | +1.59 |
| OCUL Ocular Therapeutix Inc. | New | 1.54% | +1.54 |
| CLDX Celldex Therapeutics Inc. | New | 1.27% | +1.27 |
| CMPS Compass Pathways PLC | New | 1.18% | +1.18 |
| BMY Bristol-Myers Squibb Co. | Add +1.1% | 10.57% | +1.01 |
| ENGN Engene Holdings Inc. | New | 0.97% | +0.97 |
| ZBIO Zenas Biopharma Inc. | New | 0.78% | +0.78 |
| UTHR United Therapeutics Corp. | Add +50.0% | 1.52% | +0.66 |
| PACB Pacific Biosciences of Calif | Add +200.0% | 1.13% | +0.58 |
| BIIB Biogen Inc. | New | 0.52% | +0.52 |
| LPCN Lipocine Inc. | New | 0.51% | +0.51 |
| QURE Uniqure NV | Add +227.1% | 0.94% | +0.51 |
| IDYA Ideaya Biosciences Inc. | New | 0.32% | +0.32 |
| RCUS Arcus Biosciences Inc. | New | 0.32% | +0.32 |
| RGNX Regenxbio Inc. | New | 0.32% | +0.32 |
| KPTI Karyopharm Therapeutics Inc. | New | 0.27% | +0.27 |
| RCKT Rocket Pharmaceuticals Inc. | New | 0.26% | +0.26 |
| VRDN Viridian Therapeutics Inc. | New | 0.22% | +0.22 |
| GRCE Grace Therapeutics Inc. | New | 0.13% | +0.13 |
| NVCR Novocure Ltd. | Add +33.0% | 1.26% | +0.10 |
| KYNB Kyntra Bio Inc. | New | 0.09% | +0.09 |
| QNRX Quoin Pharmaceuticals LT-ADR | New | 0.08% | +0.08 |
| PRTA Prothena Corp. PLC | Add +1.8% | 2.48% | +0.02 |
| ZNTL Zentalis Pharmaceuticals Inc. | Add +3.0% | 0.02% | +0.01 |
| QDEL Quidelortho Corp. | Add +13.8% | 0.77% | −0.44 |
| BCYC Bicycle Therapeutics PLC-ADR | Add +0.2% | 1.22% | −0.69 |
| GPCR Structure Therapeutics Inc. | Add +11.1% | 2.74% | −0.92 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 72 | $213.8M | KLAC, BMY, LRCX, NTLA, SLDB |
| Q1 2026 | 73 | $175.7M | KLAC, BMY, CMPX, LRCX, STOK |
| Q4 2025 | 68 | $170.8M | KLAC, BMY, CMPX, STOK, LRCX |
| Q3 2025 | 69 | $132.4M | KLAC, BMY, CORT, PRTA, STOK |
| Q2 2025 | 71 | $100.7M | BMY, KLAC, CORT, OVV, ACAD |
| Q1 2025 | 68 | $115.2M | BMY, CORT, ACAD, PRTA, BDSX |
| Q4 2024Amended | 68 | $122.9M | BMY, BDSX, ACAD, ELUT, PRTA |
| Q3 2024Amended | 61 | $115.5M | BMY, BDSX, ACAD, ELUT, UTHR |
| Q2 2024Amended | 60 | $108.2M | BMY, BDSX, ELUT, NBIX, SILK |
| Q1 2024Amended | 59 | $122.7M | BMY, NBIX, BDSX, ELUT, ACAD |